Get all your news in one place.
100's of premium titles.
One app.
Start reading
StockNews.com
StockNews.com
Business
Rjkumari Saxena

Is Aurinia Pharmaceuticals Poised for Growth in the Biotech Space?

Canadian company, Aurinia Pharmaceuticals Inc. (AUPH) operates as a leading commercial-stage biopharmaceutical company. The company reported impressive financial results for the third quarter of fiscal 2024. Its revenue of $67.77 million surpassed the analysts’ expectations of $57.69 million. Also, AUPH’s EPS of $0.10 was above the estimate of $0.01.

Aurinia emphasizes the development and commercialization of therapies that target various diseases with insufficient medical reach. The company’s LUPKYNIS is used to treat adult patients with active lupus nephritis.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.